Search hospitals > Missouri > Kansas City
Saint Luke's Hospital of Kansas City
Claim this profileKansas City, Missouri 64111
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Heart Failure
Conducts research for Stroke
Conducts research for Lung Cancer
437 reported clinical trials
44 medical researchers
Summary
Saint Luke's Hospital of Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Heart Failure, Stroke, Lung Cancer and other specialties. Saint Luke's Hospital of Kansas City is involved with conducting 437 clinical trials across 584 conditions. There are 44 research doctors associated with this hospital, such as Michael Gibson, Timothy Pluard, Janakiraman Subramanian, and Keith Allen, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Michael GibsonVanderbilt University/Ingram Cancer Center4 years of reported clinical research
Studies Parotid Gland Cancer
Studies Squamous Cell Carcinoma
18 reported clinical trials
37 drugs studied
Timothy PluardSaint Luke's Cancer Institute LLC1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
13 reported clinical trials
23 drugs studied
Janakiraman SubramanianSaint Luke's Hospital of Kansas City6 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
20 drugs studied
Keith Allen, MDSaint Luke's Hospital of Kansas City3 years of reported clinical research
Studies Mitral Regurgitation
Studies Mitral Valve Regurgitation
8 reported clinical trials
15 drugs studied
Clinical Trials running at Saint Luke's Hospital of Kansas City
Breast Cancer
Stroke
Lung Cancer
Amyloidosis
Non-Small Cell Lung Cancer
Breast cancer
Pancreatic Cancer
Heart Failure
Pancreatic Carcinoma
Parotid Gland Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
PF-07220060 + Letrozole
for Breast Cancer
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Recruiting2 awards Phase 34 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's Hospital of Kansas City?
Where is Saint Luke's Hospital of Kansas City located?
Who should I call to ask about financial aid or insurance network?
What insurance does Saint Luke's Hospital of Kansas City accept?
What awards or recognition has Saint Luke's Hospital of Kansas City received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.